French scientists have developed a GC?MS method, combined with a triple partition extraction step to reduce the amounts of co-extracted fats, for the determination of pesticides in meat-based baby foods.
French scientists have developed a GC–MS method, combined with a triple partition extraction step to reduce the amounts of co-extracted fats, for the determination of pesticides in meat-based baby foods. Cedric Przybylski and Christophe Segard from the Technical Centre for the Conservation of Agricultural Products (Dury-les-Amiens, France) amended the initial partition process to a three-phase system using water, acetonitrile, and hexane. The addition of hexane was designed to reduce the relatively high fat content, typically 3-20% on this type of food. The extracts were analysed by GC–MS in an ion trap with electron ionisation using a PTV injector, which was configured to evaporate at least 99% of the solvent from an injection volume of 5 µL. The GC temperature was ramped slowly to ensure optimum separation of the target analytes and to retard the passage of the remaining unwanted high-boiling coextractives. Under these conditions, 236 pesticides and transformation products, formed by oxidation, photolysis or thermolysis, could be detected and quantified within 54 minutes.The modified method should find application in regulatory labs where its lower detection limits, ease of use, and ability to cover so many pesticides will make it an attractive option for analysts.
Navigating the Impact of Funding Cuts: Voices from the Research Community
July 9th 2025Shifts in U.S. federal science funding—driven by the newly established Department of Government Efficiency (DOGE)—are causing delays, uncertainty, and program changes across academic and regulatory research institutions.
FDA Grants Breakthrough Status to AI-Enhanced GC-MS Device for Bladder Cancer Detection
July 1st 2025A new cancer detection test to analyze volatile organic compounds through urine analysis, was granted the Breakthrough Device Designation status by the U.S. FDA. The system, which is built on gas chromatography–mass spectrometry (GC–MS) and proprietary AI, generates real-time cancer risk scores.